Every coronary case demands platform decisions. Between DynamX bioadaptor and DESyne novolimus-eluting stent, the choice hinges on systematic criteria backed by trial outcomes.
Five questions structure the framework. What's the vessel diameter? INFINITY-SWEDEHEART documented zero target lesion failures in vessels ≤2.75mm with DynamX. How complex is the lesion? ACC/AHA B2/C classification predicts 33% higher restenosis risk. Which patient factors matter? Diabetes interacts specifically with lesion complexity, not independently. What anatomic challenges exist? LAD location showed 78% failure reduction with DynamX in BIOADAPTOR-RCT. What timeline matters? DynamX plateaued at six months while drug-eluting stents accumulate 2-3% annual events.
This translates evidence into procedure.